Blisibimod Seen to Lower Urine Protein Levels in Patients with Renal Involvement in Phase 3 Trial

Results of a Phase 3 clinical trial of blisibimod, by Anthera Pharmaceuticals, found that treatment significantly reduces proteinuria — excess proteins in the urine — in patients with systemic lupus erythematous (SLE). Like many B-cell mediated autoimmune diseases, lupus is associated with elevated levels of B-cell activating factor (BAFF). Blisibimod is…